New hope for liver cancer patients resistant to standard therapy
NCT ID NCT07138885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see if this approach can shrink tumors and control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?